Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage … ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ... The Lancet 387 (10024), 1163-1177, 2016 | 2079 | 2016 |
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial J Mateo, N Porta, D Bianchini, U McGovern, T Elliott, R Jones, I Syndikus, ... The Lancet Oncology 21 (1), 162-174, 2020 | 561 | 2020 |
Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019) ND James, MR Spears, NW Clarke, DP Dearnaley, JS De Bono, J Gale, ... European urology 67 (6), 1028-1038, 2015 | 513 | 2015 |
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol MR Sydes, MR Spears, MD Mason, NW Clarke, DP Dearnaley, ... Annals of Oncology 29 (5), 1235-1248, 2018 | 270 | 2018 |
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised … G Attard, L Murphy, NW Clarke, W Cross, RJ Jones, CC Parker, ... The lancet 399 (10323), 447-460, 2022 | 227 | 2022 |
STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive … ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ... Lancet 387 (10024), 1163-1177, 2016 | 214 | 2016 |
Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma DB McLaren, M McKenzie, G Duncan, T Pickles Cancer: Interdisciplinary International Journal of the American Cancer …, 1998 | 159 | 1998 |
Clinical and patient‐reported outcomes of SPARE–a randomised feasibility study of selective bladder preservation versus radical cystectomy RA Huddart, A Birtle, L Maynard, M Beresford, J Blazeby, J Donovan, ... BJU international 120 (5), 639-650, 2017 | 133 | 2017 |
The relevance of a hypoxic tumour microenvironment in prostate cancer GD Stewart, JA Ross, DB McLaren, CC Parker, FK Habib, ACP Riddick BJU international 105 (1), 8-13, 2010 | 132 | 2010 |
Hypofractionated radiotherapy for muscle invasive bladder cancer in the elderly DB McLaren, D Morrey, MD Mason Radiotherapy and oncology 43 (2), 171-174, 1997 | 93 | 1997 |
Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy DJ Storey, DB McLaren, MA Atkinson, I Butcher, LC Frew, JF Smyth, ... Annals of oncology 23 (6), 1542-1549, 2012 | 90 | 2012 |
Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: the … ND James, SJ Pirrie, AM Pope, D Barton, L Andronis, I Goranitis, S Collins, ... JAMA oncology 2 (4), 493-499, 2016 | 82 | 2016 |
The comet assay in clinical practice PL Olive Acta Oncologica 38 (7), 839-844, 1999 | 81 | 1999 |
Testicular sex cord–stromal tumours: the Edinburgh experience 1988–2002, and a review of the literature DS Conkey, GCW Howard, KM Grigor, DB McLaren, GR Kerr Clinical Oncology 17 (5), 322-327, 2005 | 69 | 2005 |
A core outcome set for localised prostate cancer effectiveness trials S MacLennan, PR Williamson, H Bekema, M Campbell, C Ramsay, ... BJU international 120 (5B), E64-E79, 2017 | 65 | 2017 |
Cyborgs in the everyday: Masculinity and biosensing prostate cancer G Haddow, E King, I Kunkler, D McLaren Science as Culture 24 (4), 484-506, 2015 | 52 | 2015 |
Clinically relevant fatigue in recurrence-free prostate cancer survivors DJ Storey, DB McLaren, MA Atkinson, I Butcher, S Liggatt, R O’Dea, ... Annals of oncology 23 (1), 65-72, 2012 | 52 | 2012 |
DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions GD Stewart, J Nanda, E Katz, KJ Bowman, JG Christie, DJG Brown, ... Biochemical pharmacology 81 (2), 203-210, 2011 | 48 | 2011 |
EPID‐based in vivo dosimetry using Dosimetry Check™: Overview and clinical experience in a 5‐yr study including breast, lung, prostate, and head and neck … WH Nailon, D Welsh, K McDonald, D Burns, J Forsyth, G Cooke, ... Journal of Applied Clinical Medical Physics 20 (1), 6-16, 2019 | 46 | 2019 |
Image-guided radiotherapy of bladder cancer: bladder volume variation and its relation to margins LP Muren, AT Redpath, H Lord, D McLaren Radiotherapy and Oncology 84 (3), 307-313, 2007 | 43 | 2007 |